Acutus Medical, Inc. (NASDAQ:AFIB) Short Interest Down 14.2% in March

Acutus Medical, Inc. (NASDAQ:AFIB) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totalling 845,200 shares, a decline of 14.2% from the March 15th total of 984,700 shares. Currently, 4.5% of the company’s shares are short sold. Based on an average trading volume of 2,250,000 shares, the short-interest ratio is currently 0.4 days.

Institutional Trading of Acutus Medical

A number of institutional investors have recently modified their holdings of the company. Bank of Montreal Can bought a new stake in shares of Acutus Medical in the first quarter valued at about $34,000. Mirabella Financial Services LLP bought a new stake in shares of Acutus Medical in the first quarter valued at about $48,000. State Street Corp lifted its holdings in shares of Acutus Medical by 11.0% in the first quarter. State Street Corp now owns 430,865 shares of the company’s stock valued at $599,000 after purchasing an additional 42,578 shares in the last quarter. Cerity Partners LLC bought a new stake in shares of Acutus Medical in the first quarter valued at about $48,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Acutus Medical by 29.7% in the first quarter. Renaissance Technologies LLC now owns 394,800 shares of the company’s stock valued at $298,000 after purchasing an additional 90,300 shares in the last quarter. 56.91% of the stock is currently owned by institutional investors.

Acutus Medical Stock Performance

AFIB stock opened at $0.17 on Tuesday. The business’s 50-day moving average price is $0.19 and its two-hundred day moving average price is $0.29. The company has a current ratio of 2.44, a quick ratio of 2.22 and a debt-to-equity ratio of 1.10. The firm has a market cap of $5.08 million, a PE ratio of -0.14 and a beta of 0.19. Acutus Medical has a 1-year low of $0.16 and a 1-year high of $1.09.

About Acutus Medical

Acutus Medical, Inc, an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs.